Management team



Ohad Karnieli (PhD, MBA)
Chief Executive Officer & Co-Founder
Dr. Karnieli earned his PhD in Biotechnology focusing on Cell & Gene Therapy from the Sacler school of Medicine at Tel Aviv University and an MBA from the Haifa University school of management. Dr. Karnieli served in several executive rolls in the field of cell therapy and medical devices with his last position being the VP of Technology & Manufacturing at Pluristem Therapeutics. A well-known expert in the field of cell therapy process development and serves on several industry committees including chairing of the process & product development committee of the International Society for Cell Therapy and an expert member in the ISO TC276 Bioprocessing committee. Dr. Karnieli is the founder of Karnieli Ltd and ADVA Biotechnology.


Vered Caplan
Chair, Board of Directors
Ms. Caplan is a highly experienced executive in the field of cell therapy and medical devices and the Chair and CEO of Orgenesis Inc. Formerly Ms. Caplan was the CEO of Kamedis, GammaCan and a director at Opticul Ltd, Nehora Photonics Ltd Ocure Ltd, Eve Medical Ltd and a biotech investment corp. Ms. Caplan has a M.Sc. in bio-medical engineering from Tel-Aviv University specialized in signal processing; management for engineers from Tel-Aviv University specialized in business development; and a B.Sc. in mechanical engineering from the Technion Institute of Technology specialized in software and cad systems.


Noam Bercovich (BSc, Eng)
Director of Development
Mr. Bercovich brings to ATVIO over 12 years of cell therapy experience starting as a development engineer, cGMP staff, cGMP manufacturing team leader, manufacturing line manager and director of process engineering at Pluristem therapeutics. Mr. Bercovich was part of the team that developed the proprietary Pluristem packed bed bioreactor and managed the bioreactor team for over 8 years.


Nufar Gross (MSc, MBA)
GMP Director
Ms. Gross has MSc in immunology and over 7 years in Biotechnology industry. Ms. Gross was development team member, development team leader, Production line manager in Pluristem therapeutics as well as production department manager and project manager in Accellta. Ms. Gross has extensive skills in management, employee’s qualification, cGMP manufacturing, technology transfer and bioprocessing.


Efrat Assa-Kunik (PhD)
Director of Business Development
Dr Assa-Kunik earned her PhD at the Weizmann Institute of Science in the fields of genetics and developmental biology and a Masters from the Ben-Gurion University in immunology and cancer research. Additionally, Dr Kunik was a postdoctoral fellow in Weizmann Institute at the department of neural biology. After her postdoc, Efrat joined Biogencell, a clinical stage biotechnology company developing therapeutic cellular products from adult stem/progenitor cells, as a Senior Scientist. In 2012 she joined Pharmaseed, Israel’s leading GLP-certified pre-clinical CRO specializing in translational and regenerative studies and act as the director of the Business Development Unit, VP business development and manager of the business development activity in USA.


Moshik Lindner (practical engineering)
Maintenance Manager
Mr. Lindner has over 6 years of experience in maintenance of cGMP production facilities at Pluristem therapeutics. Among his roles in Pluristem Mr. Lindner was a cGMP production team member, a safety delegate, designated maintenance representative in the production facility and process development team member. Mr. Lindner brings to ATVIO extensive knowledge and understanding on cleanrooms maintenance and operations and HVAC system management.


Atar Liran (MSc.)
Quality assurance Team leader
Mr. Atar Liran was appointed as Atvio Quality Assurance Team Leader in September 2016. Atar has vast experience in biopharmaceutical companies, especially in cell therapy, compliance to quality systems (FDA, GMP), product specifications, process instructions and safety requirements. Between 2011 and 2016 Mr. Liran severed as the GMP Supervisor at Medgenics, a gene-therapy company, with responsibilities for the production of autologous transplanted modified tissue for clinical trials in Israel and the US. Atar started his professional career at Protalix in the QC department. Atar Liran is holding a B.Sc. in Animal Science & Biotechnology from the Hebrew University and M.Sc. in Molecular Biology from the Weizmann Institute.